ER+ male BCa: PR-negative status tied to poorer survival in SEER analysis

  • Wei JL & al.
  • World J Surg Oncol
  • 17.12.2018

  • von Miriam Davis, PhD
  • Univadis Clinical Summaries
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

Takeaway

  • Males with estrogen receptor-positive/progesterone receptor-negative (ER+/PR) breast cancer (BCa) have worse BCa-specific survival (BCSS) and worse OS than those with ER+/PR+ BCa, according to an analysis of the US Surveillance, Epidemiology, and End Results (SEER) database.
  • Reasons may be larger tumor size, lymph node invasion, and metastasis at presentation.

Why this matters

  • ER+/PR tumors in males may warrant more aggressive treatment than ER+/PR+ tumors.

Study design

  • Population-based retrospective cohort by Chinese researchers comparing demographics, clinical characteristics, and outcome of ER+/PR (n=355) vs ER+/PR+ (n=2322) male BCa, using the SEER database (1990-2010).
  • Funding: None.

Key results

  • At diagnosis, ER+/PR patients were younger (P=.008), were more likely African American (P<.001 and had:>
  • a higher histological grade (P<.001>
  • more invasion into the lymph nodes (P=.034),
  • more metastasis (12.4% vs 6.5%; P<.001 and>
  • later stage (P=.001).
  • After median follow-up of 82 months, and despite a greater likelihood of chemotherapy (51.0% vs 36.5%; P<.001 having er>+/PR tumors was associated with worse BCSS (P<.001 and worse os by kaplan-meier survival analysis.>

    Limitations

    • Retrospective, observational design.